COVID VaccinesReturn to WorkMental Health

Belgian data finds that Moderna’s COVID vaccine creates twice as many antibodies as Pfizer’s

August 31, 2021, 7:21 AM UTC

Moderna Inc.’s COVID vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.

study of almost 2,500 workers at a major Belgium hospital system found antibody levels among individuals who hadn’t been infected with the coronavirus before getting two doses of the Moderna vaccine averaged 2,881 units per milliliter, compared with 1,108 units/mL in an equivalent group who got two jabs of the Pfizer shot.

The results, published Monday in a letter to the Journal of the American Medical Association, suggested the differences might be explained by the:

  • higher amount of active ingredient in the Moderna vaccine—100 micrograms, versus 30 micrograms in Pfizer-BioNTech
  • longer interval between doses of the Moderna vaccine—four weeks, versus three weeks for Pfizer-BioNTech

Moderna’s vaccine was associated with a two-fold risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizer’s in a review of people in the Mayo Clinic Health System in the U.S. from January to July. The results were reported in a separate study released ahead of publication and peer review on Aug. 9.

More health care and Big Pharma coverage from Fortune:

Subscribe to The Capsule, a weekly brief monitoring advances in health care and biopharma, delivered free to your inbox.